On August 5, 2021 Prescient Therapeutics Limited (ASX:PTX) reported that it is engaged in developing a robust drug pipeline comprising CAR-T and targeted therapies (PTX-100 & PTX-200) for various challenging cancers with unmet medical needs (Press release, Prescient Therapeutics, AUG 5, 2021, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-in-a-sweet-spot-with-significant-progress-in-multiple-cancer-programs [SID1234586072]). The personalised medicine approaches of the Company seek to improve patient outcomes in combating cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Furthermore, Prescient is working to rapidly expand the application of universal CAR-T therapies capable of addressing difficult-to-treat cancers.

On 4 August 2021, the Company announced its participation in Reach Markets’ ‘The Insider: Meet the CEO’ session, where PTX gave a presentation highlighting key developments in multiple cancer programs.

Prescient’s innovative pipeline in personalised medicine, Source: PTX Investor Presentation, 4 August 2021

ALSO READ: Prescient ends June quarter with notable progress in cancer programs and a healthy financial position

PTX-100 showed an excellent safety profile and exhibited encouraging activity in Phase 1b trial
In the Phase 1b basket trial, PTX-100 demonstrated an impressive safety profile and was well tolerated at the highest dose of 2,000mg/m2. In addition, no serious adverse events (SAEs) related to PTX-100 were observed during the study. Notably, the drug also exhibited clinical benefit in two T cell lymphoma (TCL) patients with aggressive disease that had not responded to 3-5 prior therapies.

The Company is now planning to conduct an expansion cohort study of PTX-100 concentrating on the treatment of TCL with a possibility of subsequent registration study. Currently, the Company anticipates enrolling up to 12 patients with T cell lymphoma (mainly Peripheral T-Cell Lymphoma or PTCL), which represents an area of considerable unmet need.

RELATED ARTICLE: Prescient takes its PTX-100 trial to next level after Phase 1b success

PTX-200 Phase 1b trial underway: Acute myeloid leukemia (AML)
The PTX-200 AML study is spearheaded by world-renowned leukemia specialist Professor Jeffrey Lancet at Moffitt Cancer Center and Dr Tara Lin at the University of Kansas Medical Center (KUMC).

Initially, PTX-200 was tested for 25 mg/m2. Having proved its safety, the AML study was advanced to a higher dose of to 35 mg/m2. The Company highlighted that the three patients treated with the 35 mg/m2 dose had achieved complete responses in the study so far. Currently, PTX is screening the second cohort at 45 mg/m2.

Moreover, PTX-200 has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration.

RELATED ARTICLE: Prescient Therapeutics’ (ASX:PTX) AML trial progresses to next dosing level

OmniCAR- A universal next-generation CAR-T
Prescient is developing next-generation products in-house. In January 2021, the oncology player disclosed its three OmniCAR programs-

In June, the Company completed another CAR-T milestone with the completion of manufacturing and delivery of crucial components of the OmniCAR platform. In addition, PTX highlighted that the binders against various cancer targets, including CLL-1, CD33, Her2, and EGFRviii, were produced by a US-based leading antibody manufacturer.

Additionally, in-silico evaluation confirmed the non-immunogenic profile of these crucial components. The results demonstrated that OmniCAR’s binding system components – SpyTag and SpyCatcher – have very low immunogenicity, lower than a panel of humanised therapeutic antibodies already approved for human use.

OnmiCAR also offers collaboration and licensing opportunities for third parties via partnerships based on targets, specific constructs as well as cell types.

Source: PTX Investor Presentation, 4 August 2021

RELATED ARTICLES:

Prescient Therapeutics reaches a major CAR-T manufacturing milestone
Positive results from immunogenicity testing send Prescient’s shares higher
Cell Therapy Enhancements (CTE) programs

Prescient has several other initiatives in progress to develop new cell therapy programs. The new programs overcome the efficiency challenges confronted by other CAR-T therapies.

CTE programs are now being undertaken at Peter MacCallum Cancer Centre, another sign of the fast-developing relationship between the two organisations. Notably, Prescient would have 100% ownership of intellectual property (IP) generated from the ongoing research on cell therapy enhancement programs.

On 4 August 2021, PTX shares closed at AU$0.185, up by 5.714%.